216 related articles for article (PubMed ID: 15243404)
1. PET/CT in diagnostic oncology.
Messa C; Bettinardi V; Picchio M; Pelosi E; Landoni C; Gianolli L; Gilardi MC; Fazio F
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):66-75. PubMed ID: 15243404
[TBL] [Abstract][Full Text] [Related]
2. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
4. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
5. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
6. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
7. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
Delbeke D; Martin WH; Patton JA; Sandler MP
Radiology; 2001 Jan; 218(1):163-71. PubMed ID: 11152796
[TBL] [Abstract][Full Text] [Related]
8. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography/computed tomography: the current technology and applications.
Mittra E; Quon A
Radiol Clin North Am; 2009 Jan; 47(1):147-60. PubMed ID: 19195540
[TBL] [Abstract][Full Text] [Related]
10. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
[TBL] [Abstract][Full Text] [Related]
11. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
Czernin J; Allen-Auerbach M; Schelbert HR
J Nucl Med; 2007 Jan; 48 Suppl 1():78S-88S. PubMed ID: 17204723
[TBL] [Abstract][Full Text] [Related]
12. Dual-modality PET/CT instrumentation-today and tomorrow.
Lonsdale MN; Beyer T
Eur J Radiol; 2010 Mar; 73(3):452-60. PubMed ID: 20096520
[TBL] [Abstract][Full Text] [Related]
13. Considerations for generic oncology FDG-PET/CT protocol preparation in drug development.
Hallett WA; Maguire RP; McCarthy TJ; Schmidt ME; Young H
IDrugs; 2007 Nov; 10(11):791-6. PubMed ID: 17968761
[TBL] [Abstract][Full Text] [Related]
14. Objective and subjective comparison of standard 2-D and fully 3-D reconstructed data on a PET/CT system.
Strobel K; Rüdy M; Treyer V; Veit-Haibach P; Burger C; Hany TF
Nucl Med Commun; 2007 Jul; 28(7):555-9. PubMed ID: 17538397
[TBL] [Abstract][Full Text] [Related]
15. Whole-body 18F-FDG PET/CT in the presence of truncation artifacts.
Beyer T; Bockisch A; Kühl H; Martinez MJ
J Nucl Med; 2006 Jan; 47(1):91-9. PubMed ID: 16391192
[TBL] [Abstract][Full Text] [Related]
16. Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma.
Freudenberg LS; Schueler AO; Beyer T; Antoch G; Kühl H; Bornfeld N; Bockisch A; Egelhof T
Surv Ophthalmol; 2004; 49(5):537-40. PubMed ID: 15325198
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
19. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
20. Overview of positron emission tomography chemistry: clinical and technical considerations and combination with computed tomography.
Koukourakis G; Maravelis G; Koukouraki S; Padelakos P; Kouloulias V
J BUON; 2009; 14(4):575-80. PubMed ID: 20148445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
